|Study Title:||Canadian Prospective Cohort Study to Understand Progression in Multiple Sclerosis (CanProCo)|
|Study Description:||CanProCo is an observational study of different factors thought to play a role in MS disease progression. Bringing together several fields of study is a powerful way to assess different aspects of progression in MS leading to: a better understanding of the biological mechanisms of progression, identification of risk factors for progression, development of biomarkers to monitor progression and predict treatment response, and inform strategies to improve the lives of people living with MS.
All these insights have the potential to improve clinical practice, and on a larger scale, affect health policy.
CanProCo participants are required to undergo a total of 6 study visits, one at study start, and one per year for an additional 5 years.
All study participants will undergo the following, at each study visit:
1) Clinical interview (comprised of the following)
a) Questionnaires and surveys to assess different parts of your lifestyle and wellbeing
b) Interview with research staff to collect information about your medical history
c) iPad based tests of your limb and brain health
2) Neurological exam (performed by the study doctor)
This exam is similar to that performed by your neurologist when you visit the MS clinic
Some participants with specific disease characteristics (e.g., diagnosed more recently) will be asked to consider the following:
1) Give a blood sample (yearly)
2) Have a research MRI (60 minutes) (at visits # 1, 2, 3, and 5)
3) Give a spinal fluid sample, but ONLY if you are already having a spinal tap for medical reasons
o A spinal tap is NEVER performed (specifically) for CanProCo research purposes
o If you have a spinal tap, you can choose to give one extra tube of fluid for the CanProCo study
o This is entirely OPTIONAL and does not affect your ability to participate otherwise
|Recruitment Dates:||2019-03-14 to 2020-09-30|
|Who can participate:||
|Location of Trial:||St. Michael’s Hospital|
|Contact Information:||Melanie Guenette
|Trial Funding:||MS Society of Canada, Biogen Canada Inc, Brain Canada Foundation, Roche, Government of Alberta|